Abstract

The final goal of this research was to improve a treatment for allergy rhinitis using chitosan-hydrocortisone silver nanoparticles based on hydrocortisone-deposited chitosan. The nanoparticles were produced by depositing hydrocortisone in chitosan, generating a reaction with highly reactive silver, and placing the nanoparticles into the nasal mucosa. Silver nanoparticles were manufactured after chitosan deposition and the optimal hydrocortisone concentration supporting the highest drug delivery efficiency was identified. For efficient DDS(Drug Delivery Systems applications, an adsorption experiment was performed before silver nanoparticle production according to the hydrocortisone concentration. In addition, a release experiment with different amounts of silver salt was performed to determine the optimal hydrocortisone and silver salt concentrations for producing chitosan-hydrocortisone silver nanoparticles. The amount released was investigated as a parameter of time. When the hydrocortisone concentration was 0.05g, the chitosan adsorption rate was highest at 48%. A release experiment was conducted at 36℃ in PBS, which is similar to the human body condition, while changing the silver salt amount. At approximately 60 hours, the absorbance was constant, indicating that hydrocortisone was emitted from the chitosan particles. In the cases of the 50㎕ reaction and 100㎕ reaction, the release rate was 14.17% and 12.92%, respectively. Otherwise, in the case of using 10㎕ silver salt solution for the reaction, 99.6% of the amount absorbed was released, showing the highest efficiency as a drug delivery agent.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call